Posted inBiotechnology
After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy
The FDA is freeing Intellia Therapeutics' CRISPR therapy from one of two clinical holds, allowing a phase 3 study to…
Posted inBiotechnology
Photon-counting CT Delivers Lower Dose with Equivalent CNR
In a groundbreaking study published in the journal Pediatric Radiology, researchers led by Narum, S.A., along with colleagues Yu, L.…
Posted inBiotechnology
Lisata reclaims China rights to solid tumor candidate ahead of acquisition
Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead…
Posted inBiotechnology
Reinforcement Learning Enhances Mental Health Education Resource Allocation
In recent years, the intersection of mental health education and artificial intelligence has opened new avenues for enhancing educational strategies…
Posted inBiotechnology
Comparing Efsitora and Daily Insulin in Type 2 Diabetes
Recent research into diabetes treatment has spotlighted a novel insulin known as Efsitora Alfa, which could potentially reshape how Type…
Posted inBiotechnology
New Treatments Target Pediatric Pulmonary Thromboembolism
In recent years, the pediatric medical community has observed a marked rise in cases of pulmonary thromboembolism (PTE) linked to…
Posted inBiotechnology
Unraveling Poaceae Chloroplast Genome Evolution Insights
In a groundbreaking study spearheaded by a team of researchers led by X. Geng, the intricate world of chloroplast genome…
Posted inBiotechnology
Linking Frailty, Nutrition, and Diet in Seniors
In an era marked by an increased focus on the health and well-being of aging populations, recent research has delved…
Posted inBiotechnology
Tilpasninger af 15-metoden i dansk praksis
In the evolving landscape of healthcare, the integration of evidence-based interventions into clinical practice remains a pivotal focal point. Recent…
Posted inBiotechnology
From gene therapies to … firearms? Italian biotech makes unexpected strategic pivot
When Genenta Science listed on the Nasdaq at the tail end of 2021, the Milan-based biotech was squarely focused on…